News

Published on 15 Mar 2024 on Benzinga

Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor...

Article preview image

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Friday, shares are trading lower after several analysts downgraded the stock after the company released the data.

Read the rest of the article
NASDAQ.IMRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

As the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and ...

Simply Wall St. · via Yahoo Finance 22 Nov 2024
Why Is Nanocap Immuneering Stock Trading Higher On Friday?

On Thursday, Immuneering Corporation (NASDAQ:IMRX) released initial response data from the first...

Benzinga · via Yahoo Finance 22 Sep 2024
Immuneering Director Acquires 7.5% More Stock

Potential Immuneering Corporation (NASDAQ:IMRX) shareholders may wish to note that the Director, ...

Simply Wall St. via Yahoo Finance 21 Mar 2024
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks...

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stock...

Investing.com 18 Mar 2024
Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering Corporation IMRX is a clinical-stage biotech company focused on developing universal-...

Zacks via Yahoo Finance 18 Mar 2024
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor...

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion ...

Benzinga 15 Mar 2024
Crude Oil Edges Lower; US Consumer Sentiment Falls In March - Cardlytics (NASDAQ:CDLX), American...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points...

Benzinga 15 Mar 2024
Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data By Investing.com

Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data

Investing.com 15 Mar 2024
Immuneering stock target cut to $15 by Needham

Immuneering stock target cut to $15 by Needham

Investing.com 15 Mar 2024
Immuneering stock price target cut to $16 from $21

On Friday, Chardan Capital Markets adjusted its price target forImmuneering Corporation (NASDAQ:I...

Investing.com 15 Mar 2024

Copyright Statfolio @ 2025

Social Accounts